Ultragenyx Pharmaceutical RARE
NASDAQ RARE
$14.90 -0.13 (-0.86%)
As of: Oct 1, 2026 · 12:15 PM EDT

Ultragenyx Pharmaceutical (RARE) Total Non-Current Liabilities (2013 - 2026)

Updated

Ultragenyx Pharmaceutical (RARE) reported Total Non-Current Liabilities of $429 million for Q2 2026, up 15.2% from $372.52 million a year earlier and up 6.2% from the prior quarter.

Analysis

Ultragenyx Pharmaceutical (RARE) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends

At the end of FY2025, Ultragenyx Pharmaceutical posted Total Non-Current Liabilities of $465 million, up 8.6% from FY2024.

  • Total Non-Current Liabilities has increased for four consecutive years, with a five-year compound annual growth rate of 11.5% (FY2020 to FY2025).
  • By year, Total Non-Current Liabilities came in at $428 million in FY2024 (+21.0%), $353.69 million in FY2023 (+11.2%), $318.01 million in FY2022 (+28.2%) and $248.05 million in FY2021 (-8.0%).
  • Five-year quarterly Total Non-Current Liabilities spans a low of $203.05 million in Q3 2021 and a high of $465 million in Q4 2025.
  • Year over year, Total Non-Current Liabilities has now increased in each of the last 18 quarters, with growth averaging 13.0% over the last eight quarters.
  • The high point for year-over-year Total Non-Current Liabilities in five years was Q2 2022 (growth of 44.5%); the low point was Q3 2021 (a decline of 25.1%).
  • Per Business Quant data, the three quarters before Q2 2026 came in at $404 million (Q1 2026), $465 million (Q4 2025) and $417.55 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 105.99 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 106.45 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 80.25 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 48.34 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -967.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 81.11 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 36.04 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 100.86 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 5.92 Bn
10 Ultragenyx Pharmaceutical 1.48 Bn -321.29 Mn 180.00 Mn 429.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 429.00 Mn
Mar 31, 2026 404.00 Mn
Dec 31, 2025 465.00 Mn
Sep 30, 2025 417.55 Mn
Jun 30, 2025 372.52 Mn
Mar 31, 2025 373.88 Mn
Dec 31, 2024 428.00 Mn
Sep 30, 2024 361.85 Mn
Jun 30, 2024 343.86 Mn
Mar 31, 2024 318.09 Mn
Dec 31, 2023 353.69 Mn
Sep 30, 2023 330.43 Mn
Jun 30, 2023 301.28 Mn
Mar 31, 2023 276.44 Mn
Dec 31, 2022 318.01 Mn
Sep 30, 2022 287.58 Mn
Jun 30, 2022 283.61 Mn
Mar 31, 2022 231.97 Mn
Dec 31, 2021 248.05 Mn
Sep 30, 2021 203.05 Mn
API Access

Ultragenyx Pharmaceutical Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=RARE&period=max&api_key=YOUR_API_KEY